Sector News

Reeling from an FDA rejection, Telesta sheds 15% of its staff

March 9, 2016
Life sciences

Montreal biotech Telesta Therapeutics is cutting 15% of its payroll to conserve cash as the company works to get its once-rejected cancer drug back on track.

Most of the layoffs will affect Telesta’s manufacturing operation, management said, and the company is simultaneously slashing its expenditures. The biotech reported cash and equivalents totaling $20.3 million at the end of 2015.

Telesta, which trades on the Toronto exchange, is trying to pick up the pieces after the FDA rejected its application to win approval in bladder cancer last month. The company’s drug, MCNA, failed to satisfy regulators’ demands, and the FDA asked Telesta to conduct at least one more Phase III trial to establish the treatment’s efficacy and safety.

Now Telesta is requesting a so-called Type A meeting with the FDA, angling to sit down with agency staff to “obtain clarity” on what it needs to do to win approval, the company said in a statement.

“In parallel, we are working with our board of directors to review of all of our strategic options over the next few months,” CEO Michael Berendt said in a statement. “We are very aware that this review must be conducted and completed in a timely fashion to ensure that we conserve our key cash resources.”

Since MCNA’s rejection in early February, Telesta has been hinting that it may try to sell itself, with Berendt saying at the time that “the current climate of uncertainty in the financial markets has created opportunities for well-capitalized companies that were simply not available even a few months ago.”

Last year, Telesta flipped the European rights to MCNA to Ipsen, banking a $10 million upfront payment with a shot at $127 million more if the drug wins approval overseas.

By Damian Garde

Source: Fierce Biotech

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend